ProMark® Risk Score

This policy provides limited coverage for the ProMark test to help determine suitability for conservative (active surveillance) management for patients with early-stage, needle biopsy–proven prostate cancer. Coverage is intended to guide selection of patients who may avoid definitive surgery or radiation.

"ProMark is covered to assist in determining which patients with early-stage, needle biopsy–proven prostate cancer are suitable for conservative (active surveillance) management instead of definitiv..."

Sign up to see full coverage criteria, indications, and limitations.